Press Releases October 7, 2026 04:05 PM

Lifecore Biomedical to Participate at Upcoming Industry Conferences

Lifecore Biomedical Announces Participation in Multiple Upcoming Industry Conferences to Showcase CDMO Capabilities

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
LFCR

Lifecore Biomedical, a Nasdaq-listed contract development and manufacturing organization specializing in injectable pharmaceutical products, announced its participation in three upcoming industry conferences in Boston. The company aims to engage with prospective customers to discuss its process development and manufacturing services, highlighting its expertise in sterile injectables and complex formulations.

Lifecore Biomedical to Participate at Upcoming Industry Conferences
LFCR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Lifecore Biomedical will be present at three industry events in Boston during October and November 2026, including CDMO Live Americas and American Pharma Manufacturing & Outsourcing Summit.
  • The company’s leadership will hold meetings with potential customers to discuss development and manufacturing services for injectable drug programs.
  • A panel presentation will focus on designing devices for delivering high-dose/high viscosity peptides and biologics, underscoring Lifecore's technical expertise.

CHASKA, Minn., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at three upcoming industry events. 

At each conference, Lifecore leaders will host meetings with prospective customers to discuss process development and manufacturing services for injectable programs.  Details regarding Lifecore’s participation are as follows:

  • CDMO Live Americas:
    Booth number: C19 
    Conference Dates: October 19-21, 2026
    Location: Boston, MA

  • Partnership Opportunities in Drug Development (PODD)
    Booth number: 109
    Conference Dates: October 29-30, 2026
    Location: Boston, MA

    Ryan Swanson, Ph.D., director of Lifecore’s Manufacturing Science & Technology (MS&T) group, will be a panel speaker at the following session: 
    Designing Devices to Deliver High-Dose/High Viscosity Peptides & Biologics
    Fri, Oct 30 | 03:50 PM - 04:20 PM
    Grand Ballroom

  • American Pharma Manufacturing & Outsourcing Summit 
    Booth number: TBD
    Conference Dates: November 20-23, 2026
    Location: Boston, MA

If you are interested in meeting with Lifecore during this event, please reach out to us at: [email protected].

About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.

Contact Information:
Vida Strategic Partners
Stephanie Diaz (Investors)
415-675-7401
[email protected]

Jennifer Arcure (Media)
917-603-0681
[email protected]

Lifecore Biomedical
Ryan D. Lake (CFO)
952-368-6244
[email protected]


Risks

  • The impact of conference participation on new business development is uncertain and depends on successful interactions and follow-up.
  • Competition in the CDMO sector remains intense, which may limit Lifecore’s ability to expand its client base despite the events.
  • External factors such as regulatory changes or supply chain disruptions could affect Lifecore’s operational capabilities, indirectly influencing the effectiveness of marketing efforts at conferences.

More from Press Releases

CNH Names Paul Dick, President, North America Nov 20, 2026 Harmony Biosciences to Participate in Upcoming Investor Conferences Nov 19, 2026 Pure Cycle Announces Record Financial Results For the Year Ended August 31, 2026 Nov 18, 2026 Sachem Capital Reports Third Quarter 2026 Results Nov 16, 2026 Inter&Co Delivers Record 3Q26 Net Income of US$76.1 Million, With Strong Growth, Higher Margin and Better Efficiency Nov 12, 2026